Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Autolus Therapeutics Plc ADR
(NQ:
AUTL
)
3.500
+0.130 (+3.86%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Autolus Therapeutics Plc ADR
< Previous
1
2
3
4
5
6
Next >
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
December 12, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
Dow Tumbles 100 Points; Silver Rises Over 2%
December 09, 2022
U.S. stocks traded mostly lower toward the end of trading with the Dow Jones dropping 100 points on Friday
Via
Benzinga
US Stocks Turn Higher; Nasdaq Rises 40 Points
December 09, 2022
U.S. stocks traded slightly midway through trading with the Nasdaq gaining over 40 points on Friday
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
December 09, 2022
Via
Benzinga
Why Autolus Therapeutics Stock Is Crashing Today
December 09, 2022
The biopharmaceutical company announced the pricing of a secondary stock offering.
Via
The Motley Fool
Autolus Therapeutics: Q3 Earnings Insights
November 03, 2022
Autolus Therapeutics (NASDAQ:AUTL) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Moderna In-Licenses Autolus' Technology For mRNA-Based Cancer Therapeutics
October 12, 2022
Via
Benzinga
Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session
December 09, 2022
Gainers Ambrx Biopharma Inc. (NYSE: AMAM) shares jumped 551.4% to $2.67 after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate.
Via
Benzinga
US Stocks Edge Lower; Producer Prices Increase Higher Than Expected
December 09, 2022
U.S. stocks traded slightly lower this morning following the release of PPI data
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 09, 2022
Via
Benzinga
Autolus Therapeutics' Leukemia Trial Meets Primary Goal Of Remission Rate, Shares Fall After $150M Capital Raise
December 09, 2022
Via
Benzinga
Why Autolus Therapeutics Shares Are Trading Lower By Around 26%; Here Are 28 Stocks Moving Premarket
December 09, 2022
Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares rose 48.2% to $6.03 in pre-market trading after jumping over 20% on Thursday. Baudax Bio initiated Phase II clinical trial evaluating BX1000 in patients...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
December 09, 2022
The trading week is almost complete but we've still got the biggest pre-market stock movers to go over for Friday morning!
Via
InvestorPlace
Autolus Announces Pricing of Public Offering
December 08, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
December 08, 2022
Via
Benzinga
Autolus Announces Proposed Public Offering in the United States
December 08, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life Sciences
December 08, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis
December 08, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces handover of first clean rooms of new Stevenage, UK, manufacturing facility
November 30, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
November 15, 2022
Via
Benzinga
Autolus Therapeutics to Present Three Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2022
November 03, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Reports Third Quarter 2022 Financial Results and Operational Progress
November 03, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Report Third Quarter 2022 Financial Results on November 3, 2022
October 21, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
Moderna exercises option to license proprietary targeting technology from Autolus
October 12, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing
October 05, 2022
Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all...
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
11 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 05, 2022
Gainers Bionano Genomics (NASDAQ:BNGO) stock increased by 9.8% to $2.24. The company's market cap stands at $649.9 million.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
October 05, 2022
It's time for another overview of the biggest pre-market stock movers for Wednesday as we cover the news behind share movement this morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 04, 2022
Gainers
Via
Benzinga
Autolus Therapeutics Stock Jumps After Bristol Myers Pact For Safety Switch System
October 04, 2022
Via
Benzinga
Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session
October 04, 2022
Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.